Yuriko Nagane
Overview
Explore the profile of Yuriko Nagane including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
594
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Watanabe G, Takai Y, Nagane Y, Kubota T, Yasuda M, Akamine H, et al.
Front Immunol
. 2025 Jan;
15:1502721.
PMID: 39763650
International consensus guidance and Japanese clinical guidelines for myasthenia gravis (MG) recommend achieving minimal manifestations or better status (MM-or-better) as the severity component of the treatment goal. However, the subjective...
2.
Yasuda M, Uzawa A, Kuwabara S, Suzuki S, Akamine H, Onishi Y, et al.
J Neuroimmunol
. 2024 Oct;
397:578465.
PMID: 39454316
No abstract available.
3.
Sugimoto T, Suzuki S, Uzawa A, Yamawaki T, Masuda M, Minami N, et al.
J Neurol Sci
. 2024 Aug;
464:123154.
PMID: 39142082
Introduction/aims: The common presentations of statin intolerance are muscle-specific symptoms. Although statins are one type of drug reported to cause myasthenic worsening, myasthenic worsening has not been recognized as statin...
4.
Uzawa A, Suzuki S, Kuwabara S, Akamine H, Onishi Y, Yasuda M, et al.
BMC Neurol
. 2024 Apr;
24(1):139.
PMID: 38664714
Background: Non-motor symptoms in myasthenia gravis (MG) are rarely confirmed. Although there are some small cohort studies, a large-systemic survey has not yet been performed. Methods: We investigated the incidence...
5.
Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis
Tokuyasu D, Suzuki S, Uzawa A, Nagane Y, Masuda M, Konno S, et al.
Ann Clin Transl Neurol
. 2024 Apr;
11(5):1338-1346.
PMID: 38572524
Objective: Eculizumab and ravulizumab are complement protein C5 inhibitors, showing efficacy and tolerability for patients with anti-acetylcholine receptor-positive (AChR+) generalized myasthenia gravis (gMG) in phase 3 clinical trials and subsequent...
6.
Suzuki S, Uzawa A, Nagane Y, Masuda M, Konno S, Kubota T, et al.
Neurol Clin Pract
. 2024 Mar;
14(3):e200276.
PMID: 38544885
Background And Objectives: Efgartigimod, which has been well tolerated and efficacious in individuals with generalized myasthenia gravis (MG), is available in Japan not only for the treatment of anti-acetylcholine receptor-positive...
7.
Yasuda M, Uzawa A, Kuwabara S, Suzuki S, Akamine H, Onishi Y, et al.
J Neuroimmunol
. 2023 Nov;
385:578241.
PMID: 37952282
This study included 51 patients with muscle-specific kinase antibody-positive myasthenia gravis (MuSK-MG) from a Japanese multicenter survey to examine clinical features and outcomes. Median onset age was 37 years and...
8.
Uzawa A, Suzuki S, Kuwabara S, Akamine H, Onishi Y, Yasuda M, et al.
J Neurol Neurosurg Psychiatry
. 2023 Jan;
94(6):467-473.
PMID: 36693723
Background: Early fast-acting treatment (EFT) is the aggressive use of fast-acting therapies such as plasmapheresis, intravenous immunoglobulin and/or intravenous high-dose methylprednisolone (IVMP) from the early phases of treatment. EFT is...
9.
Impact of Early Treatment with Intravenous High-Dose Methylprednisolone for Ocular Myasthenia Gravis
Uzawa A, Suzuki S, Kuwabara S, Akamine H, Onishi Y, Yasuda M, et al.
Neurotherapeutics
. 2023 Jan;
20(2):518-523.
PMID: 36607596
The efficacy of intravenous high-dose methylprednisolone (IVMP) in ocular myasthenia gravis (MG) has not been fully established. This study aimed to elucidate the effects of early intervention with IVMP for...
10.
Imai T, Suzuki S, Nagane Y, Uzawa A, Murai H, Utsugisawa K
Front Neurol
. 2020 Sep;
11:868.
PMID: 32982912
Treatment with oral corticosteroids at high doses with an escalation and de-escalation schedule is effective against myasthena gravis (MG). In fact, the use of corticosteroids has led to a reduction...